MOIC are delighted that their pre-project application to the Northern Ireland Connected Health Innovation Centre (CHIC) to explore the use of the AstraZeneca Apollo dashboard for identification of patients and other digital tools to self-monitor and improve patient management with Heart Failure and Type 2 Diabetes has been successful. This connected health research project involves collaboration with industrial (AstraZeneca, Healthcare Analytics), healthcare (MOIC, SHSCT) and academic (CHIC in UU) partners.

This will directly help patients in Northern Ireland suffering from Type 2 Diabetes and Heart Failure. It is well known that Type 2 Diabetes is associated with increased cardiovascular morbidity and mortality. In Northern Ireland (NI), there are approx. 80,000 people living with Type 2 Diabetes (T2DM) and 15,000 people living with Heart Failure (HF).

Currently, GP practices have access to a Diabetes Care Dashboard (Apollo), developed by Astra Zeneca. The Dashboard is an informatics-based diagnostic solution that enables GP practices to extract, analyse and review primary care held data to assist with patient care.

This funding will now enable us to explore how information provided from Apollo could be used to identify patients with both diabetes and heart failure who could be eligible to use digital tools to self-monitor and improve the management of their condition. In the SHSCT there are around 1300 “active” patients in the system. Systems to effectively identify, prioritise and guide management patients within an acceptable timescale are required. Without this, patients may inevitably wait and potentially miss the window of opportunity for clinical benefit.

We will be working directly with the SHSCT cardiology team and hope to identify which healthcare technologies would be the most useful for these patients to use at home and to explore the facilitators and barriers to the use of healthcare technologies.